Skip to main content

Advertisement

Table 1 Baseline characteristics for patients receiving high-potency statins

From: Effect of high-potency statins on HbA1c in patients with or without diabetes mellitus

  Patients with diabetes (n = 276)   Patients without diabetes (n = 659)  
  Atorvastatin Pitavastatin Rosuvastatin P-value Atorvastatin Pitavastatin Rosuvastatin p-value
Number of patients 87 70 119 - 221 151 287 -
Mean follow-up days 262 313 303 0.60 243 314 352 0.01
Male, % 75.9 65.7 62.2 0.11 52.0 53.0 57.5 0.43
Age, years, mean ± SD 66.2 ± 11 65.8 ± 12 67.5 ± 12 0.56 68.1 ± 11 67.4 ± 11 66.0 ± 12 0.12
Disease, %
 Diabetes 96.6 97.1 97.4 0.93 0 0 0 -
 Hypertension 72.4 57.1 70.6 0.09 48.4 58.3 55.0 0.30
 Myocardial infarction 12.6 11.4 18.5 0.33 17.6 17.2 19.5 0.80
 Chronic heart failure 18.4 14.3 21.0 0.52 16.7 17.2 22.0 0.27
 Renal disease 12.6 5.7 16.0 0.12 11.7 17.9 10.8 0.09
 Liver disease 8.0 8.6 11.8 0.63 9.5 7.3 13.6 0.10
 Pulmonary disease 13.8 14.3 12.6 0.94 14.9 13.2 19.1 0.22
CCI, mean 1.3 1.4 1.3 0.50 1.2 1.3 1.3 0.88
Concomitant medications, %
 Antidiabetics (insulin) 86.2 (10.3) 81.4 (10.0) 80.7 (8.6) 0.56 0 0 0 -
 ACEIs or ARBs 47.1 47.1 47.1 0.99 35.3 40.4 33.8 0.39
 Beta-blockers 25.3 10.0 31.9 0.003 21.2 26.5 22.0 0.45
 Thiazides 4.6 8.6 6.8 0.60 4.5 1.3 5.9 0.08
 CCBs 39.1 28.6 41.1 0.21 43.0 34.4 31.7 0.03
 Antipsychotics 0 0 4.2 0.03 3.2 3.3 1.7 0.49
Laboratory tests
 HbA1c, %, mean (n) 6.9 (74) 7.3 (58) 7.0 (97) 0.14 5.7 (115) 5.8 (72) 5.8 (153) 0.67
 Ordering Llipids, % 92.0 94.3 93.3 0.85 86.9 83.4 86.8 0.58
  1. Abbreviations: ACEIs angiotensin converting enzyme inhibitors, ARBs angiotensin-receptor blockers, CCBs calcium-channel blockers, CCI Charlson Comorbidity Index, HbA1c hemoglobin A1c, SD standard deviation